Breaking News

Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement

Abzena will work with Immunome to produce the antibody cocktail for clinical testing.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Immunome, Inc., a biopharma company utilizing a human memory B cell platform to develop antibody therapeutics, and Abzena, a partner research organization for discovery to cGMP manufacturing services for biologics, entered an agreement for Immunome’s IMM-BCP-01, an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens.   Abzena will work with Immunome to produce the antibody cocktail for clinical testing. In July 2020...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters